AllSci News
J&J completes USD 1b Firefly acquisition to add pan-KRAS degrader capabilities
Johnson & Johnson (NYSE: JNJ) has completed its acquisition of Firefly Bio, Inc. for USD 1 billion in cash, adding the company's proprietary Firelink...
Processa acquires CNS-penetrant BTK inhibitor with USD 200m financing for three Phase II programs
Vero Beach, Florida-based Processa Pharmaceuticals (Nasdaq: PCSA) has acquired Vidya Therapeutics, a private clinical-stage company developing VT-7208, a...
FDA advisory committee votes against Capricor's deramiocel effectiveness for DMD cardiomyopathy
The US FDA's Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 9 to 3 against the effectiveness of deramiocel (CAP-1002) for the...
Verdiva advances oral amylin strategy with first-in-human study of VRB-103
London and San Francisco-based Verdiva Bio Limited has dosed the first patient in a Phase I single ascending dose study of VRB-103, a once-weekly oral...
FDA clears Iksuda's CA242-targeted ADC for Phase I study in GI cancers
UK-based Iksuda Therapeutics has received US FDA clearance of its investigational new drug application for IKS04, a CA242-directed antibody-drug conjugate...
Biogen Q2'26: Lupus, AMR and Dravet catalysts take center stage
Biogen Inc. (Nasdaq: BIIB) Q2 2026 earnings call, held on July 29, 2026, centered on five imminent registrational readouts across lupus, antibody-mediated...
Scripps advances dual-target mammarenavirus antivirals with NIAID funding
Scripps Research Institute has received a USD 1.62 million NIAID R01 grant to advance preclinical development of two novel small-molecule inhibitors...
Caldera taps reverse merger to advance TL1A × IL-23 bispecific
Cambridge, Massachusetts-based Caldera Therapeutics has agreed to merge with Synlogic, Inc. (OTC: SYBX) in an all-stock transaction, with the combined...
Adjuvia raises USD 8m for preclinical-stage mitochondrial therapy
San Francisco-based Adjuvia Therapeutics has closed an USD 8 million Series Seed financing to advance its lead mitochondrial disease therapy candidate,...
AbCellera adds Vertex as latest TCE platform partner in autoimmune disease
Vancouver-based AbCellera Biologics (Nasdaq: ABCL) has announced a collaboration with Vertex Pharmaceuticals (Nasdaq: VRTX) to discover and develop...
Qnovia bets on antimicrobial peptides with exclusive UVA deal
Irvine, California-based Qnovia, Inc. has secured a worldwide exclusive license to a preclinical antimicrobial peptide, designated D8, from the University...
LB Pharma raises USD 150m to expand LB-102 zinto three neuropsychiatric indications
New York-based LB Pharmaceuticals Inc (Nasdaq: LBRX) has announced a USD 150 million private placement, with the proceeds earmarked primarily to expand its...
GSK/Hansoh's B7-H3 ADC set for China filing after hitting Phase III endpoint in osteosarcoma
China-based Hansoh Pharmaceutical Group (HKEX: 03692) announced that HS-20093, its proprietary B7-H3-directed antibody-drug conjugate, met the primary...
Shape Therapeutics secures funding to advance one-time gene therapy for Parkinson's disease.
Seattle-based Shape Therapeutics has received a research grant from The Michael J. Fox Foundation for Parkinson's Research to fund IND-enabling studies of...
GSK accelerates 20-plus Phase III starts through GBP 1.9b savings program
GSK plc's Q2 2026 earnings call, held on July 28, 2026, revealed one of the most aggressive late-stage pipeline acceleration programs the company has...
The AllSci Brief
Free, systematic R&D and deal news. Daily.